KLRS Kalaris Therapeutics, Inc. - Common Stock
NASDAQ · Biotechnology · Visualizza su SEC EDGAR ↗ chiudi Ott 2, 2026 10-K/10-Q Ago 11, 2026
$2,70
· % dell'intervallo 52 sett.
· sopra il minimo
· al massimo
$2,51minimo 52 sett.
$11,55massimo 52 sett.
Capitalizzazione di Mercato (MRQ)
$64M
P/E
-0.9
EPS
$-2.85
i tuoi badge
Intervallo 52 sett.
$3–$12
Rating Analisti
STRONG BUY
Prezzo Obiettivo
$19
P/E
-0.9
ROE
-65.8%
Margine di Profitto Netto
·
La tua barra dei badge è vuota — aggiungi una metrica a piacere in questa pagina.
KLRS Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane
Prezzo
$2.70
Capitalizzazione di Mercato (MRQ)
$64M
P/E
-0.9
EPS
$-2.85
ROE
-65.8%
Intervallo 52 sett.
$3–$12
KLRS Grafico del prezzo delle azioni OHLCV giornaliero con indicatori tecnici — panoramica, zoom e personalizza la tua visualizzazione
intervallo
barre
La granularità delle barre si adatta al periodo selezionato — passa il mouse sul grafico per vedere apertura/massimo/minimo/chiusura di una barra.
Split azionari
| Data ex-dividendo | Split | Tipo |
|---|---|---|
| 16 Gennaio 2025 | 1-for-23 | Inverso |
Performance decennale Andamento di ricavi, utile netto, margini e EPS
Ricavi·2019-12-31 → 2019-12-31
EPS$-2.852021-12-31 → 2025-12-31
Flusso di cassa libero$-39M2020-12-31 → 2025-12-31
Valutazione e Rapporti
Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?
| Metrica | Tendenza 5 anni | KLRS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| P/E | -0.9media 5 anni ≈-33.2 | ≈-33.2 | · | · | |
| P/B (MRQ) | 1.1media 5 anni ≈16.0 | ≈16.0 | 1.3 | Più costoso | |
| Price / FCF (Prezzo / FCF) | -1.6 | · | · | · | |
| Price / Cash Flow (Prezzo / Flusso di cassa) | -1.6media 5 anni ≈-24.4 | ≈-24.4 | · | · | |
| Price / Tangible Book (Prezzo / Valore contabile tangibile) | 0.8media 5 anni ≈45.1 | ≈45.1 | · | · |
La mediana dei peer viene calcolata su base standardizzata per metrica e potrebbe non corrispondere sempre alla base TTM/MRQ mostrata per questo titolo.
Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC
| Metrica | Tendenza 5 anni | KLRS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| ROA | -67.9%media 5 anni ≈-61.8% | ≈-61.8% | -69.2% | In linea | |
| ROE | -65.8%media 5 anni ≈-184.8% | ≈-184.8% | -72.9% | In linea | |
| ROIC | -58.6%media 5 anni ≈-82.4% | ≈-82.4% | -70.9% | Di prim'ordine |
Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio
| Metrica | Tendenza 5 anni | KLRS | media 5 anni | Mediana dei peer | Verdetto |
|---|---|---|---|---|---|
| Rapporto corrente (MRQ) | 11.0media 5 anni ≈12.9 | ≈12.9 | 3.3 | Liquidità elevata | |
| Quick Ratio | 12.1media 5 anni ≈12.7 | ≈12.7 | 3.2 | Liquidità elevata | |
| Interest Coverage (Copertura degli interessi) | -32.0 | · | -32.0 | In linea |
Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y
Nessun dato per questo gruppo di rapporti al momento
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti
Nessun dato per questo gruppo di rapporti al momento
Dati fondamentali insufficienti per calcolare questo gruppo di rapporti.
valore · ≈ media 5 anni · mediana del settore · giudizio rispetto alla mediana
Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili
Sorpresa media
-21.7%
Prossimo report
Nov 10, 2026
| Periodo | Rapporto | EPS Actual | EPS Stimato | Sorpresa |
|---|---|---|---|---|
| 30 Giugno 2026 | Ago 19, 2026 | $-0.48 | $-0.50 | 4.9% |
| 31 Marzo 2026 | Mag 20, 2026 | $-0.46 | $-0.53 | 13.8% |
| 31 Dicembre 2025 | $-0.51 | $-0.54 | 5.9% | |
| 30 Settembre 2025 | $-0.64 | $-0.67 | 3.9% | |
| 30 Giugno 2025 | $-0.61 | $-0.53 | -15.0% | |
| 31 Marzo 2025 | $-2.52 | $-0.79 | -218.8% | |
| 30 Giugno 2024 | $-1.15 | $-2.46 | 53.3% |
Fondamentali Completi Tutte le metriche per anno — conto economico, stato patrimoniale, rendiconto finanziario
Conto Economico
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | · | · | · | · | · | · | $165.0K | |
| R&D Expense | $31M | $45M | $133M | $119M | $121M | $50M | $16M | |
| SG&A Expense | $15M | $7M | $48M | $52M | $49M | $22M | $11M | |
| Operating Expenses | $46M | $52M | $200M | $171M | $170M | $71M | $27M | |
| Operating Income | $-46M | $-52M | $-200M | $-171M | $-170M | $-71M | $-27M | |
| Interest Expense | $1M | $3M | · | · | · | · | · | |
| Interest Income | · | $5M | $6M | $2M | $1M | $1M | $2M | |
| Other Non-op | $3M | $188.0K | $4M | $351.0K | $-2M | $195.0K | $797.0K | |
| Pretax Income | $-43M | $-69M | $-191M | $-169M | $-171M | $-70M | $-24M | |
| Income Tax | $0 | $0 | $-126.0K | $-265.0K | $1M | · | · | |
| Net Income | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | $-24M | |
| EPS (Basic) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| EPS (Diluted) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · | |
| Shares (Basic) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| Shares (Diluted) | 15,267,817 | 1,335,925 | 4,524,226 | 76,654,856 | 62,782,126 | · | · | |
| EBITDA | $-46M | $-65M | $-200M | $-170M | · | $-71M | · |
Stato Patrimoniale
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98M | $2M | $90M | $106M | $202M | $123M | $61M | |
| Short-term Investments | $20M | $0 | $94M | $128M | $46M | $234M | $65M | |
| Prepaid Expense | $827.0K | $967.0K | $3M | $7M | $5M | $5M | $676.0K | |
| Current Assets | $119M | $3M | $188M | $243M | $253M | $361M | $127M | |
| PP&E (Net) | · | · | · | $930.0K | $2M | $812.0K | $350.0K | |
| PP&E (Gross) | · | · | $2M | $2M | $2M | $904.0K | $369.0K | |
| Accum. Depreciation | · | · | · | $1M | $281.0K | $92.0K | $19.0K | |
| Other Non-current Assets | $953.0K | $410.0K | $122.0K | $612.0K | $1M | · | · | |
| Total Assets | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Accounts Payable | $1M | $2M | $7M | $3M | $8M | $963.0K | $630.0K | |
| Accrued Liabilities | · | $5M | $10M | $14M | $20M | $8M | $5M | |
| Current Liabilities | $10M | $25M | $28M | $24M | $38M | $12M | $9M | |
| Capital Leases | $1M | $0 | $17M | $28M | $23M | $5M | $9M | |
| Total Liabilities | $43M | $57M | $45M | $53M | $61M | $18M | $18M | |
| Common Stock | $2.0K | $0 | $0 | $9.0K | $7.0K | $7.0K | · | |
| Paid-in Capital | $239M | $20M | $802M | $691M | $522M | $478M | $4M | |
| Retained Earnings | $-160M | $-117M | $-656M | $-466M | $-297M | $-125M | $-55M | |
| AOCI | $6.0K | $0 | $-62.0K | $-468.0K | $-155.0K | $-112.0K | $68.0K | |
| Stockholders' Equity | $79M | $-97M | $-45M | $225M | $225M | $353M | $-52M | |
| Liabilities + Equity | $122M | $6M | $191M | $277M | $287M | $371M | $139M | |
| Shares Outstanding | 22,902,418 | 1,356,431 | 4,962,997 | 93,093,243 | 63,565,886 | 61,931,255 | 2,099,740 |
Flusso di cassa
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $398.0K | $723.0K | $189.0K | $73.0K | $19.0K | |
| Stock-based Comp | $2M | $895.0K | $41M | $41M | $44M | $9M | $3M | |
| Deferred Tax | $0 | $0 | · | · | · | · | · | |
| Restructuring | · | $10M | · | · | · | · | · | |
| Other Non-cash | · | · | $25M | $-15M | · | $-529.0K | · | |
| Operating Cash Flow | $-38M | $-21M | $-124M | $-142M | $-106M | $-61M | $-20M | |
| CapEx | $200.0K | · | · | · | $26.0K | $235.0K | $339.0K | |
| Investing Cash Flow | $-20M | $95M | $38M | $-80M | $186M | $-169M | $-65M | |
| Stock Issued | $42M | · | · | $126M | · | · | · | |
| Net Stock Activity | $42M | · | · | $126M | · | · | · | |
| Financing Cash Flow | $155M | $19M | $70M | $127M | $232.0K | $292M | $121M | |
| Net Change in Cash | $97M | $-2M | $-16M | $-96M | $80M | $62M | $36M | |
| Taxes Paid | $0 | $0 | $220.0K | $613.0K | · | · | · | |
| Free Cash Flow | $-39M | · | · | · | · | $-61M | · | |
| Levered FCF | $-40M | · | · | · | · | · | · |
Redditività
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| ROA | -67.9% | -38.0% | -81.4% | -59.9% | · | -27.4% | · | |
| ROE | -65.8% | -491.2% | -111.6% | -70.6% | · | -19.2% | · | |
| ROIC | -58.6% | -57.8% | -137.0% | -76.1% | · | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 12.2 | 22.6 | 6.6 | 10.0 | · | 29.4 | · | |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · | 29.0 | · | |
| Interest Coverage | -32.0 | · | · | · | · | · | · |
Per Azione
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.44 | $22.48 | $1.28 | $2.41 | · | $5.70 | · | |
| Cash Flow / Share | $-2.51 | $-13.52 | $-1.20 | $-1.85 | · | · | · | |
| Cash / Share | $4.28 | $23.47 | $0.79 | $1.14 | · | $1.98 | · | |
| EPS (TTM) | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 | · | · |
Valutazione (TTM)
| Metrica | Tendenza | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-43M | $-69M | $-190M | $-169M | $-172M | $-70M | · | |
| Market Cap | $193M | $49M | $1.79B | $10.98B | · | $54.75B | · | |
| P/E | -3.0 | -0.2 | -0.4 | -53.6 | -108.6 | · | · | |
| P/B | 2.5 | 0.4 | 12.2 | 48.9 | · | 155.1 | · | |
| P / Tangible Book | 2.5 | · | · | 48.9 | 84.0 | 155.1 | · | |
| P / Cash Flow | -5.0 | -0.7 | -14.3 | -77.3 | · | -900.4 | · | |
| P / FCF | -5.0 | · | · | · | · | -896.9 | · | |
| Earnings Yield | -33.8% | -535.9% | -269.1% | -1.9% | -0.92% | · | · |
Conto Economico
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expense | $9M | $8M | $7M | $9M | $8M | $6M | $4M | $36M | $3M | $2M | $33M | $34M | $35M | $31M | $28M | $30M | |
| SG&A Expense | $3M | $4M | $4M | $4M | $4M | $4M | $3M | $2M | $976.0K | $602.0K | $10M | $13M | $12M | $13M | $12M | $13M | |
| Operating Expenses | $12M | $12M | $11M | $13M | $12M | $10M | $7M | $38M | $4M | $3M | $62M | $47M | $47M | $43M | $40M | $43M | |
| Operating Income | $-12M | $-12M | $-11M | $-13M | $-12M | $-10M | $-7M | $-38M | $-4M | $-3M | $-62M | $-47M | $-47M | $-43M | $-40M | $-43M | |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1M | $1M | $815.0K | $499.0K | $78.0K | · | · | · | · | · | · | |
| Interest Income | · | · | · | · | · | · | · | $1M | $1M | $1M | $1M | $2M | $2M | $1M | $898.0K | $668.0K | |
| Other Non-op | $871.0K | $977.0K | $803.0K | $847.0K | $906.0K | $193.0K | $64.0K | $31.0K | $66.0K | $27.0K | $1M | $1M | $521.0K | $723.0K | $986.0K | $210.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | $-60M | $-44M | $-45M | · | $-39M | $-42M | |
| Income Tax | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $-126.0K | $0 | $0 | $0 | $-415.0K | $0 | |
| Net Income | $-12M | $-11M | $-10M | $-12M | $-11M | $-10M | $-22M | $-38M | $-6M | $-3M | $-60M | $-44M | $-45M | $-41M | $-38M | $-42M | |
| EPS (Basic) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| EPS (Diluted) | $-0.48 | $-0.46 | $0.92 | $-0.64 | $-0.61 | $-2.52 | $-16.75 | $-28.16 | $-4.26 | $-2.60 | $-40.78 | $-0.39 | $-0.48 | $-0.44 | $-0.32 | $-0.50 | |
| Shares (Basic) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| Shares (Diluted) | 23,797,306 | 23,723,618 | · | 18,701,708 | 18,701,286 | 4,053,140 | · | 1,352,265 | 1,325,706 | 1,312,552 | · | 113,894,188 | 94,625,837 | 93,303,672 | · | 84,948,837 | |
| EBITDA | $-12M | $-12M | · | $-13M | $-12M | $-10M | · | $-6M | $-8M | $-32M | · | $-47M | $-47M | $-43M | · | $-43M |
Stato Patrimoniale
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $34M | $98M | $42M | $88M | $101M | $2M | $117M | $105M | $86M | $90M | $96M | $197M | $116M | $106M | $124M | |
| Short-term Investments | $50M | $63M | $20M | $35M | · | · | $0 | $5M | $25M | $54M | $94M | $118M | $50M | $87M | $128M | $140M | |
| Prepaid Expense | $2M | $861.0K | $827.0K | $1M | $3M | $1M | $967.0K | $626.0K | $230.0K | $771.0K | $3M | $6M | $5M | $7M | $7M | $6M | |
| Current Assets | $96M | $98M | $119M | $78M | $92M | $102M | $3M | $123M | $130M | $141M | $188M | $220M | $253M | $212M | $243M | $272M | |
| PP&E (Net) | · | · | · | · | · | · | · | · | · | · | · | $673.0K | $759.0K | $844.0K | $930.0K | $943.0K | |
| PP&E (Gross) | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $2M | · | |
| Other Non-current Assets | $2M | $2M | $953.0K | $976.0K | $691.0K | $410.0K | $410.0K | · | · | · | $122.0K | $1M | $684.0K | $490.0K | $612.0K | $734.0K | |
| Total Assets | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Accounts Payable | $1M | $905.0K | $1M | $494.0K | $4M | $2M | $2M | $51.0K | $110.0K | $765.0K | $7M | $4M | $5M | $4M | $3M | $5M | |
| Accrued Liabilities | · | · | · | · | · | · | · | $1M | $2M | $5M | $10M | $16M | $17M | $12M | $14M | $14M | |
| Current Liabilities | $9M | $8M | $10M | $6M | $8M | $7M | $25M | $1M | $2M | $8M | $28M | $33M | $31M | $25M | $24M | $21M | |
| Capital Leases | $1M | $1M | $1M | $1M | · | · | $0 | · | $8M | $16M | $17M | $20M | $23M | $26M | $28M | $20M | |
| Total Liabilities | $42M | $41M | $43M | $39M | $40M | $39M | $57M | $1M | $11M | $24M | $45M | $53M | $54M | $51M | $53M | $40M | |
| Common Stock | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $2.0K | $0 | $11.0K | $11.0K | $11.0K | $0 | $11.0K | $11.0K | $9.0K | $9.0K | $9.0K | |
| Paid-in Capital | $240M | $239M | $239M | $192M | $191M | $191M | $20M | $818M | $813M | $807M | $802M | $792M | $782M | $701M | $691M | $681M | |
| Retained Earnings | $-182M | $-171M | $-160M | $-150M | $-138M | $-127M | $-117M | $-697M | $-693M | $-686M | $-656M | $-596M | $-552M | $-507M | $-466M | $-428M | |
| AOCI | $-73.0K | $-49.0K | $6.0K | $6.0K | · | · | $0 | $-134.0K | $-139.0K | $-138.0K | $-62.0K | $-200.0K | $-225.0K | $-301.0K | $-468.0K | $-563.0K | |
| Stockholders' Equity | $58M | $69M | $79M | $42M | $53M | $64M | $-97M | $121M | $120M | $120M | $146M | $195M | $229M | $194M | $225M | $253M | |
| Liabilities + Equity | $100M | $110M | $122M | $81M | $93M | $103M | $6M | $123M | $131M | $144M | $191M | $248M | $283M | $244M | $277M | $294M | |
| Shares Outstanding | 23,804,981 | 22,992,291 | 22,902,418 | 18,702,418 | 18,702,418 | 18,702,418 | 1,356,431 | 115,438,119 | 115,312,411 | 114,881,765 | 4,962,997 | 113,966,594 | 113,716,018 | 93,427,990 | 93,093,243 | 92,640,109 |
Flusso di cassa
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | · | · | · | $141.0K | $86.0K | $85.0K | $86.0K | $86.0K | $85.0K | |
| Stock-based Comp | $644.0K | $580.0K | $333.0K | $638.0K | $591.0K | $374.0K | $280.0K | $-10M | $-5M | $31.0K | $10M | $10M | $10M | $10M | $9M | $11M | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | $0 | |
| Restructuring | · | · | · | · | · | · | · | $100.0K | $500.0K | $10M | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | · | · | · | · | · | · | · | · | $-1M | · | · | |
| Operating Cash Flow | $-11M | $-12M | $-7M | $-11M | $-13M | $-7M | $-8M | $43M | $36M | $-5M | $-31M | $-34M | $-27M | $-32M | $-32M | $-35M | |
| CapEx | · | · | $17.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Investing Cash Flow | $20M | $-50M | $15M | · | · | · | · | $20M | $30M | $40M | $25M | $-67M | $38M | $42M | $14M | $-39M | |
| Stock Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | |
| Financing Cash Flow | $-377.0K | $-2M | $48M | $0 | $0 | $107M | $8M | $12M | $5M | $7M | $11.0K | $0 | · | · | $292.0K | $126M | |
| Net Change in Cash | $9M | $-64M | $56M | $-46M | $-13M | $100M | $-274.0K | $-16M | $7M | $2M | $-6M | $-101M | $81M | $10M | $-18M | $53M | |
| Taxes Paid | · | · | · | · | · | · | · | · | · | · | $-131.0K | $1.0K | · | · | $-390.0K | $0 |
Redditività
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROA | -12.0% | -10.2% | · | -11.7% | -10.1% | -8.2% | · | -2.2% | -2.9% | -15.6% | · | -16.3% | -18.8% | -17.3% | · | -13.8% | |
| ROE | -20.8% | -16.4% | · | -14.6% | -13.1% | -11.1% | · | -2.6% | -3.5% | -19.3% | · | -19.7% | -23.4% | -21.4% | · | -16.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -24.0% | -20.6% | · | · | · |
Liquidità e Solvibilità
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.0 | 12.2 | · | 12.9 | 12.0 | 14.3 | · | 86.8 | 55.1 | 18.5 | · | 6.7 | 8.3 | 8.5 | · | 13.1 | |
| Quick Ratio | 10.7 | 12.0 | · | 12.7 | 11.6 | 14.1 | · | 86.3 | 54.9 | 18.4 | · | 6.5 | 8.1 | 8.1 | · | 12.7 | |
| Interest Coverage | · | · | · | · | · | -7.2 | · | · | · | · | · | · | · | · | · | · |
Per Azione
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.42 | $2.98 | · | $2.24 | $2.84 | $3.42 | · | $1.05 | $1.04 | $1.05 | · | $1.71 | $2.01 | $2.07 | · | $2.73 | |
| Cash Flow / Share | · | $-0.49 | · | · | · | $-1.84 | · | · | · | $-0.39 | · | · | · | $-0.34 | · | · | |
| Cash / Share | $1.81 | $1.50 | · | $2.27 | $4.73 | $5.40 | · | $1.01 | $0.91 | $0.75 | · | $0.84 | $1.73 | $1.24 | · | $1.34 | |
| EPS (TTM) | $-0.66 | $-0.79 | · | $-20.52 | $-48.04 | $-51.69 | · | $-75.80 | $-48.03 | $-44.25 | · | $-1.63 | $-1.74 | $-1.95 | · | $-2.80 |
Valutazione (TTM)
| Metrica | Tendenza | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income TTM | $-44M | $-44M | · | $-55M | $-82M | $-76M | · | $-107M | $-113M | $-153M | · | $-169M | $-167M | $-166M | · | $-189M | |
| Market Cap | $97M | $133M | · | $108M | $50M | $150M | · | $2.15B | $1.92B | $1.99B | · | $5.64B | $8.89B | $8.47B | · | $16.81B | |
| P/E | -6.2 | -7.3 | · | -0.3 | -0.1 | -0.2 | · | -0.2 | -0.3 | -0.4 | · | -30.3 | -44.9 | -46.5 | · | -64.8 | |
| P/B | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Tangible Book | 1.7 | 1.9 | · | 2.6 | 0.9 | 2.4 | · | 17.7 | 15.9 | 16.6 | · | 28.9 | 38.8 | 43.7 | · | 66.4 | |
| P / Cash Flow | · | -11.5 | · | · | · | -20.2 | · | · | · | -45.0 | · | · | · | -263.6 | · | · | |
| Earnings Yield | -16.2% | -13.7% | · | -355.0% | -1799.2% | -643.7% | · | -407.4% | -288.8% | -254.8% | · | -3.3% | -2.2% | -2.1% | · | -1.5% |
Periodo più recente a sinistra · valori nulli mostrati come ·
Bilanci Conto economico, stato patrimoniale, flusso di cassa — annuale, ultimi 5 anni
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Utile netto | $-43M | $-69M | $-190M | $-169M | $-172M |
| EPS Diluito | $-2.85 | $-51.77 | $-42.09 | $-2.20 | $-2.74 |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Rapporto corrente | 12.2 | 22.6 | 6.6 | 10.0 | · |
| Quick Ratio | 12.1 | 22.6 | 6.5 | 9.6 | · |
| Metrica | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Flusso di cassa libero | $-39M | · | · | · | · |
Proprietari istituzionali (13F) 57 filer · $75.8M totale · Aggiornato al 30 Giugno 2026
Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.
Detentori
57
Valore detenuto
$75.8M
Nuove posizioni
9
Posizioni chiuse
11
Attività istituzionale — Q2 2026 vs trimestre precedente
| Nuove posizioni | Posizioni chiuse | Aumentato | Diminuito | Variazione netta delle azioni |
|---|---|---|---|---|
| 9 (-6 vs trimestre precedente) | 11 (+4 vs trimestre precedente) | 18 (+2 vs trimestre precedente) | 9 (+2 vs trimestre precedente) | -548K |
Confrontato con Q1 2026. Le dichiarazioni SEC Form 13F sono dovute entro 45 giorni dalla fine del trimestre più un breve margine per i dichiaranti in ritardo — i trimestri ancora all'interno di questa finestra vengono saltati a favore della coppia più recente completamente riportata.
| Istituzione | Valore | Azioni | % di 13F tracciati | Tipo |
|---|---|---|---|---|
| SAMSARA BIOCAPITAL, LLC | $52.426.382 | 12.881.175 | 69,20% | Azioni |
| RTW INVESTMENTS, LP | $5.291.000 | 1.300.000 | 6,98% | Azioni |
| VANGUARD GROUP INC | $2.471.147 | 292.790 | 3,26% | Azioni |
| Alyeska Investment Group, L.P. | $2.330.836 | 572.687 | 3,08% | Azioni |
| Siren, L.L.C. | $1.773.698 | 435.798 | 2,34% | Azioni |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.622.758 | 398.712 | 2,14% | Azioni |
| Ikarian Capital, LLC | $1.465.201 | 360.000 | 1,93% | Azioni |
| UBS Group AG | $1.066.873 | 262.131 | 1,41% | Azioni |
| RENAISSANCE TECHNOLOGIES LLC | $607.859 | 149.351 | 0,80% | Azioni |
| MARSHALL WACE, LLP | $566.549 | 139.201 | 0,75% | Azioni |
| GEODE CAPITAL MANAGEMENT, LLC | $464.287 | 114.037 | 0,61% | Azioni |
| Woodline Partners LP | $407.000 | 100.000 | 0,54% | Azioni |
| ADAR1 Capital Management, LLC | $407.000 | 100.000 | 0,54% | Azioni |
| WHI TRUST Co LLC | $396.797 | 97.493 | 0,52% | Azioni |
| RAYMOND JAMES FINANCIAL INC | $395.457 | 97.164 | 0,52% | Azioni |
| CITADEL ADVISORS LLC | $389.792 | 95.772 | 0,51% | Azioni |
| BOOTHBAY FUND MANAGEMENT, LLC | $375.502 | 92.261 | 0,50% | Azioni |
| Verdad Advisers, LP | $326.809 | 80.297 | 0,43% | Azioni |
| MORGAN STANLEY | $294.367 | 72.326 | 0,39% | Azioni |
| VANGUARD FIDUCIARY TRUST CO | $269.349 | 66.179 | 0,36% | Azioni |
| BlackRock, Inc. | $221.580 | 54.442 | 0,29% | Azioni |
| Fortis Capital Advisors, LLC | $162.800 | 40.000 | 0,21% | Azioni |
| Belpointe Asset Management LLC | $162.800 | 40.000 | 0,21% | Azioni |
| Pale Fire Capital SE | $161.278 | 39.626 | 0,21% | Azioni |
| Squarepoint Ops LLC | $157.814 | 38.775 | 0,21% | Azioni |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | $132.275 | 32.500 | 0,17% | Azioni |
| Stonepine Capital Management, LLC | $122.597 | 30.122 | 0,16% | Azioni |
| Connor, Clark & Lunn Investment Management Ltd. | $122.128 | 30.007 | 0,16% | Azioni |
| Trexquant Investment LP | $121.030 | 29.737 | 0,16% | Azioni |
| STATE STREET CORP | $107.896 | 26.510 | 0,14% | Azioni |
| NORTHERN TRUST CORP | $105.165 | 25.839 | 0,14% | Azioni |
| Velan Capital Investment Management LP | $101.750 | 25.000 | 0,13% | Azioni |
| TWO SIGMA INVESTMENTS, LP | $97.057 | 23.847 | 0,13% | Azioni |
| WealthTrust Asset Management, LLC | $83.093 | 20.416 | 0,11% | Azioni |
| Independent Advisor Alliance | $73.769 | 18.125 | 0,10% | Azioni |
| RBF Capital, LLC | $70.781 | 17.391 | 0,09% | Azioni |
| Quadrature Capital Ltd | $67.265 | 16.527 | 0,09% | Azioni |
| GOLDMAN SACHS GROUP INC | $65.340 | 16.054 | 0,09% | Azioni |
| DIMENSIONAL FUND ADVISORS LP | $64.991 | 15.958 | 0,09% | Azioni |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $57.879 | 14.221 | 0,08% | Azioni |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | $50.875 | 12.500 | 0,07% | Azioni |
| Sigma Planning Corp | $41.380 | 10.167 | 0,05% | Azioni |
| FMR LLC | $31.770 | 7.806 | 0,04% | Azioni |
| Tower Research Capital LLC (TRC) | $10.419 | 2.560 | 0,01% | Azioni |
| Steward Partners Investment Advisory, LLC | $9.015 | 2.215 | 0,01% | Azioni |
| Vanguard Global Advisers, LLC | $2.951 | 725 | 0,00% | Azioni |
| BARCLAYS PLC | $1.233 | 303 | 0,00% | Azioni |
| Strengthening Families & Communities, LLC | $1.091 | 268 | 0,00% | Azioni |
| BNP PARIBAS FINANCIAL MARKETS | $212 | 52 | 0,00% | Azioni |
| JPMORGAN CHASE & CO | $211 | 50 | 0,00% | Azioni |
Attivisti e proprietari del 5%+ 4 partecipazioni
Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.
| Depositante | Depositato | Partecipazione | Stato | Scopo | Deposito |
|---|---|---|---|---|---|
| Samsara BioCapital, L.P., Samsara BioCapital GP, LLC, Samsara Opportunity Fund, L.P., Samsara Opportunity Fund GP, LLC, Srinivas Akkaraju ×4 depositi | 22 Maggio 2026 | 54,20% | Modifica | · | SEC |
| ElevateBio, LLC (2) | 05 Agosto 2022 | · | Deposito iniziale | · | SEC |
| F2 MG Ltd. (2), F2-TPO Investments, LLC (2), F2 MC, LLC (2), F2 Capital I 2020 LLC (2), F2 Bioscience AV 2022 LLC (2), Globeways Holdings Ltd. (2), Globeways Holdings II Ltd. (2), Morana Jovan-Embiricos (2) | 05 Agosto 2022 | · | Deposito iniziale | · | SEC |
| ElevateBio LLC (2) | 13 Agosto 2020 | · | Deposito iniziale | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insider aziendali 32 insider · 14 dirigenti · 20 direttori
| Insider | Ruolo | Ultima attività | Azioni possedute | Acquisti 12m | Vendite 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Andrew Oxtoby | President and Chief Executive Officer | 19 Marzo 2026 A | · | 0 | 0 | $0 |
| Vikas Sinha | Officer Title: President, Chief Financial Officer and Chief Executive Officer | 21 Febbraio 2025 S | 49.129 | 0 | 0 | $0 |
| Diana Brainard | Chief Executive Officer | 19 Novembre 2024 S | 723.363 | 0 | 0 | $0 |
| Liisa Ann Bayko | Chief Financial Officer | 20 Luglio 2026 A | · | 0 | 0 | $0 |
| Matthew Gall | Chief Financial Officer | 19 Marzo 2026 A | · | 0 | 0 | $0 |
| Amy O'Leary Vandekop | VP, Corporate Controller | 27 Agosto 2026 A | · | 0 | 0 | $0 |
| Matthew Feinsod | Chief Medical Officer | 19 Marzo 2026 A | 4.030 | 0 | 0 | $0 |
| Brett R Hagen | Chief Accounting Officer | 19 Marzo 2026 A | 0 | 0 | 1 | $-12.869 |
| Edward Miller | General Counsel | 21 Febbraio 2025 S | 6.517 | 0 | 0 | $0 |
| Cintia Piccina | Chief Commercial Officer | 03 Luglio 2023 A | 147.000 | 0 | 0 | $0 |
| Ann M. Leen | Chief Scientific Officer | 02 Febbraio 2023 A | 124.006 | 0 | 0 | $0 |
| Jeroen B Van Beek | Chief Commercial Officer | 16 Novembre 2022 S | 333.726 | 0 | 0 | $0 |
| Ercem Atillasoy | This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer T | 21 Ottobre 2022 S | 131.372 | 0 | 0 | $0 |
| Agustin Melian | Chief Medical Officer | 04 Ottobre 2021 S | 453.529 | 0 | 0 | $0 |
| Laurie Keating | Direttore | 01 Agosto 2026 A | · | 0 | 0 | $0 |
| Napoleone Ferrara | Direttore | 03 Giugno 2026 A | 504.000 | 0 | 0 | $0 |
| Michael Dybbs | Direttore | 03 Giugno 2026 A | · | 0 | 0 | $0 |
| Morana Jovan-Embiricos | Direttore | 03 Giugno 2026 A | 100.197 | 0 | 0 | $0 |
| David Hallal | Direttore | 03 Giugno 2026 A | 2.143.662 | 0 | 0 | $0 |
| Anthony P Adamis | Direttore | 03 Giugno 2026 A | · | 0 | 0 | $0 |
| Srinivas Akkaraju | Direttore | 03 Giugno 2026 A | 11.444.503 | 0 | 0 | $0 |
| Leone D Patterson | Direttore | 03 Giugno 2026 A | · | 0 | 0 | $0 |
| Samir Chandrakant Patel | Direttore | 10 Aprile 2025 A | 100.800 | 0 | 0 | $0 |
| Derek N. Adams | Direttore | 06 Giugno 2024 A | 70.000 | 0 | 0 | $0 |
| Malcolm Brenner | Direttore | 06 Giugno 2024 A | 100.197 | 0 | 0 | $0 |
| Juan Vera | Direttore | 06 Giugno 2024 A | 2.409.928 | 0 | 0 | $0 |
| Shawn Tomasello | Direttore | 06 Giugno 2024 A | 70.000 | 0 | 0 | $0 |
| Jeffrey S Bornstein | Direttore | 06 Giugno 2024 A | 110.197 | 0 | 0 | $0 |
| ElevateBio, LLC | Direttore | 28 Luglio 2022 A | 16.674.766 | 0 | 0 | $0 |
| ANSBERT GADICKE | Direttore | 28 Luglio 2022 A | 16.674.766 | 0 | 0 | $0 |
| John Robert Wilson | Direttore | 25 Maggio 2021 A | 3.164.954 | 0 | 0 | $0 |
| Gilead Sciences, Inc. | Proprietario del 10% | 27 Giugno 2023 P | 16.635.286 | 0 | 0 | $0 |
Insider dai depositi SEC Modulo 3/4/5; netto = solo acquisti/vendite di mercato
Proprietà ETF Posseduti da 5 ETF
Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.
| Fondo | Peso | Unità | Aggiornato al | Fonte |
|---|---|---|---|---|
| IWC · iShares Trust | 0,01% | 25.753 SH | 11 Settembre 2026 | Giornaliero |
| DCOR · Dimensional ETF Trust | 0,00% | 3.296 NS | 31 Luglio 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 137.373 SH | 19 Agosto 2026 | Giornaliero |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 255.337 SH | 19 Agosto 2026 | Giornaliero |
| DFAC · Dimensional ETF Trust | 0,00% | 2.614 NS | 31 Luglio 2026 | N-PORT |
KLRS Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo
rating · 14 analisti
COMPRA
Target mediano
$20.00
+640,7%
6 42,9%
Acquisto forte
6 42,9%
Compra
2 14,3%
Mantieni
0 0,0%
Vendi
0 0,0%
Vendita forte
Target Price a 12 Mesi
7 analisti · 2026-09-30Target medio $18.71 +593,1%
← Sotto tutti i target
Prezzo attuale $2.70
Basso$7.00
Media$18.71
Alto$25.00
Confronto Peer (GICS sub-settore industriale) Metriche chiave rispetto ai pari del settore
Base FY, prezzi alla chiusura dell'ultimo anno fiscale di ciascuna società.
| Ticker | Capitalizzazione di Mercato | P/E | Rev YoY | Margine Netto | ROE | Margine lordo |
|---|---|---|---|---|---|---|
| KLRS | $193M | -3.0 | · | · | -65.8% | · |
| INKT | · | -3.8 | 4.5% | -6931.8% | 63.4% | · |
| FRMM | · | · | · | -6881.3% | -368.1% | · |
| ACET | · | -0.5 | · | · | · | · |
| BOLD | $27M | -0.5 | · | · | -46.7% | · |
| CNTB | $159M | -2.8 | -99.8% | -86687.5% | -97.9% | · |
| CLNN | $64M | · | -41.5% | -13086.5% | 200.2% | · |
| EXOZ | $92M | -10.0 | · | · | -172.3% | · |
| XLO | $3M | -0.2 | 589.9% | -80.0% | -165.5% | · |
| INMB | $41M | -0.8 | 257.1% | -91866.0% | -175.3% | · |
Le Mie Metriche La tua watchlist personale — righe selezionate da Fondamentali Completi
Scegli le metriche che contano per te: fai clic sul + accanto a qualsiasi riga in Fondamentali Completi sopra.
La tua selezione è salvata e ti segue su tutti i ticker.
Fonte: SEC 10-Q depositato Ago 11, 2026